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Abstract: Background: The emergence of multidrug-resistant organisms (MDROs) is a global public 
health issue, severely hindering clinicians in administering appropriate antimicrobial therapy. Drug 
repurposing is a drug development strategy, during which new pharmacological applications are 
identified for already approved drugs. From the viewpoint of the development of virulence 
inhibitors, inhibition of quorum sensing (QS) is a promising route because various important 
features in bacterial physiology and virulence are mediated by QS-dependent gene expression. 
Methods: Forty-five pharmacological agents, encompassing a wide variety of different chemical 
structures and mechanisms of action, were tested during our experiments. The antibacterial activity 
of the compounds was tested using the broth microdilution method. Screening and semi-
quantitative assessment of QS-inhibition by the compounds was performed using QS-signal 
molecule-producing and indicator strains. Results: Fourteen pharmaceutical agents showed 
antibacterial activity in the tested concentration range, while eight drugs (namely 5-fluorouracil, 
metamizole-sodium, cisplatin, methotrexate, bleomycin, promethazine, chlorpromazine, and 
thioridazine) showed dose-dependent QS-inhibitory activity in the in vitro model systems applied 
during the experiments. Conclusions: Virulence inhibitors represent an attractive alternative strategy 
to combat bacterial pathogens more efficiently. Some of the tested compounds could be considered 
potential QS-inhibitory agents, warranting further experiments involving additional model systems 
to establish the extent of their efficacy. 
Keywords: drug repurposing; non-antibiotics; antimicrobials; pharmaceuticals; quorum sensing; 
quorum quenching; screening 
 
1. Introduction 
The introduction of antibiotics into clinical medicine was one of the main prerequisites for the 
development of our present-day healthcare; previously deadly infections have suddenly become 
treatable, and the introduction of various medical interventions (invasive surgery, organ 
transplantation) and specialties (oncological care, neonatology) became possible [1,2]. The emergence 
of multidrug-resistant organisms (MDROs) is a global public health issue, which severely hinders 
clinicians in defining appropriate patient treatment options and treatment regimens [3,4]; the 
ramifications of the spread of drug-resistant pathogens are biggest in developing countries, 
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significantly contributing to morbidity and mortality [5,6]. Based on their overall impact (mortality-
wise and economically), the group of “ESKAPE” pathogens (this acronym was first proposed by 
Louis B. Rice in 2008), namely E: Enterococcus faecium, S: Staphylococcus aureus or recently 
Stenotrophomonas maltophilia, K: Klebsiella pneumoniae or recently C: Clostridioides difficile, A: 
Acinetobacter baumannii, P: Pseudomonas aeruginosa, E: Enterobacter spp., or recently Enterobacteriaceae) 
present the most clinical challenges [7]. Some of these bacteria have also been included in the priority 
pathogens list, which was developed for pharmaceutical companies by the World Health 
Organization (WHO) to guide the development of new antimicrobial drugs [8–10]. Some of the main 
public health authorities (e.g., the WHO, the European Center for Disease Prevention and Control 
(ECDC), and the Centers for Disease Control and Prevention in the US (CDC)) have all published 
reports on the global impact of bacterial drug resistance and urged for global action to be taken [11–
14]; among these publications; however, the O’Neill report (sequestered by the National Health 
Service (NHS) of the United Kingdom) is probably the most pessimistic, projecting 10 million deaths 
per year by 2050 and 100 billion USD worth of economic burden [15]. In addition to their 
inappropriate use in animal husbandry and human medicine, one of the main concerns regarding the 
therapy of MDROs is the unavailability of novel antibacterial agents [16–18]. The absolute costs of 
antimicrobial research and development (R&D), the financial risks associated with the organization 
of clinical trials, the inevitable and rapid emergence of drug-resistant mutants against these new 
drugs and the comparatively modest return on investment (ROI; which is a performance measure 
used to evaluate the efficiency of an investment) has resulted in pharmaceutical companies shifting 
their interests towards the therapy of chronic illnesses or leaving behind the antimicrobial research 
programs entirely [19–22]. This has resulted in a ‘dry’ antibiotic pipeline and no new broad-spectrum 
antibiotics since the introduction of the fluoroquinolones in the 1980s [23,24]. 
In lieu of new antibiotics, novel strategies have been proposed to combat bacterial pathogens 
more efficiently—among other things, combination therapy (the use of two or more existing 
antibiotics simultaneously) and the use of adjuvants (non-antibiotic drugs co-administered with an 
existing antibiotic) all present possible alternatives [25,26]. These adjuvants include agents already 
used in clinical practice, such as monoclonal antibodies (e.g., bezlotoxumab, neutralizing 
Clostridioides difficile toxin B) [27], β-lactamase inhibitors (e.g., clavulanic acid, avibactam) [28], and 
others, such as efflux pump inhibitors (EPIs; compounds capable of inhibiting bacterial transporter 
proteins that utilize proton motive force or the hydrolysis of ATP to remove various chemicals from 
bacterial cells) [29,30], modulators of bacterial membrane potential and membrane permeabilizers 
[26]. However, it’s worth noting that at present, none of the abovementioned EPIs or membrane 
permeabilizers can be used in clinical practice, due to the very high concentrations required for them 
to be effective, which usually corresponds to debilitating toxicity in vivo [29,30]. Another promising 
approach to treat bacterial infections is through the use of virulence inhibitors (or ‘pathoblockers’) 
[31]. The rationale behind the use of these compounds is that they do not affect the viability of 
bacterial cells in vivo; instead, they inhibit the synthesis or expression of bacterial virulence factors 
(e.g., exotoxins, secreted bacterial enzymes, biofilm) which are key in their pathogenesis, or modulate 
their genetic plasticity (i.e., competence) [32–35]. The potential advantage of these agents (compared 
to antibiotics) is that the selection pressure exerted by these drugs (and consequently, the chance of 
resistance development) is expected to be much lower; therefore, the rapid emergence of drug-
resistant mutants is unlikely [36,37]. Some reports also suggest that anti-virulence drugs may have 
minor effects on the gut microbiome: they should be able to exert their activity without causing 
‘collateral damage’ [38,39]. 
Bacterial quorum sensing (QS) is a distinct mechanism of cell-cell communication, during which 
bacteria can ‘sense’ the density of cells in the surrounding environment, resulting in the expression 
or suppression of specific genes [40,41]. Surrounding bacterial cell population density is established 
by the detection of diffusible signal molecules produced by surrounding cells, in addition, self-
produced signals are also detected (activating positive feed-back circuits); if the concentration of 
these signal molecules (or autoinducers) reaches a critical concentration, transcription changes occur 
in various genes, which are important for benefits in fitness and reproductive success in their specific 
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niche [40,42,43]. The phenomenon of QS was first described in 1968 by Kempner and Hanson in Vibrio 
fischeri (postulating that the culture media contained a luminescence inhibitor, which was removed 
if large numbers of bacteria were present [44]); however, the true mechanism of QS (namely, the 
initiation of phenotypic changes by the accumulation of autoinducers secreted by bacteria) was 
reported by Nealson et al. in 1970 [45], and Eberhard et al. in 1972 [46]. QS-signal molecules 
encompass a wide variety of structurally different molecules: in Gram-positive bacteria, peptide-
based signal molecules (AIPs, autoinducing peptides) are most frequently detected, while in Gram-
negatives, acyl-homoserine lactone-derivatives (AHLs) are the most prevalent; interestingly, some 
signal molecule-types (e.g., AI-2, a derivative of dihydroxy-2,3-pentanedione) may be detected by a 
wide range of bacteria, while others (e.g., Pseudomonas quinolone signal (PQS), diffusible signal factor 
(DSF)) are specific to one or a very few species [40–43,47,48]. The elimination or inhibition of QS-
signal transmission is termed quorum quenching (QQ), which may be mediated by the use of signal-
antagonists, inhibition of signal sensing, or synthesis, influencing bacteria on the level of gene 
expression and by the degradation of these signal molecules [42,47]. Synthetic molecules (i.e., quorum 
quenching based on inhibition) may inhibit signal transduction mechanisms relevant in virulence 
factor-expression of relevant pathogens, therefore disarming them in vivo [41,49,50]. From the 
viewpoint of the development of virulence inhibitors, quorum quenching is a promising route, 
because various important bacterial features in physiology and virulence (e.g., production of toxic 
shock syndrome toxin in Staphylococcus aureus, elastase in P. aeruginosa, protease in V. cholerae; activity 
of bacterial secretion systems (e.g., Salmonella species) and efflux pumps (e.g., P. aeruginosa, Escherichia 
coli), biofilm-production (e.g., P. aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia); 
induction of bacterial competence (e.g., Streptococcus pneumoniae), motility (e.g., P. aeruginosa), 
adhesion (e.g., E. coli, Klebsiella pneumoniae) and pigment-production (e.g., Chromobacterium violaceum, 
Serratia marcescens, P. aeruginosa)) are mediated by QS-dependent gene expression [31,40,51,52]. Due 
to its promise for future applications in human medicine, research on quorum sensing and quorum 
quenching has garnered significant attention in the last 15–20 years (see Supplementary Figure S1 for 
bibliometric assessment). 
Drug repurposing (also called drug re-profiling or repositioning) is a drug development 
strategy, during which new pharmacological uses are identified for already approved drugs, outside 
of their original designated medical indications [39,53]. This strategy offers various advantages: the 
chemical and technological aspect of these molecules are already established, the toxicity, safety and 
pharmacokinetic profile of the drug is known; therefore, early stages of the drug development 
process (preclinical in vitro and animal models, Phase I–II clinical trials) may be avoided, leading to 
substantial savings for the pharmaceutical companies [39,53,54]. Although the costs of organizing 
Phase III–IV trials are still considerable, if the new indication for the drugs is appropriate, drug 
companies may still expect sizeable ROIs. Previously, drug repurposing was mainly based on 
serendipitous discoveries or retrospective analyses of clinical data; nowadays, there are initiatives to 
systematically screen the existing drug pool for off-target effects, which may be suitable for the 
development of additional clinical indications [39,53,54]. Examples of the success of drug 
repurposing include the use of thalidomide (morning sickness → multiple myeloma, erythema 
nodosum leprosum), minoxidil (hypertension → alopecia), ketoconazole (antifungal drug → Cushing 
syndrome), aspirin (analgesia → colorectal cancer), and sildenafil (angina pectoris → erectile 
dysfunction → pulmonary hypertension) in new clinical indications [53]. 
Drug repurposing is also a promising strategy in the therapy of bacterial infections: many 
pharmaceuticals have secondary mechanisms of action (some of which are not fully characterized), 
which allows them to be efficacious against various pathogens, either as directly acting antibacterial 
agents or as virulence inhibitors [55]. For this reason, there is interest in the screening of the existing 
pool of pharmaceutical agents as anti-virulence drugs; however, there are significant gaps in 
knowledge in this field [56–58]. The aim of our present study was to assess the suitability of a selection 
of non-antibiotic pharmacological agents as QS-inhibitors, with various in vitro bacterial model 
systems, using disk-diffusion based QS-inhibitory (DDBQSI) assays. 
2. Results and Discussion 
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2.1. Antibacterial Activity 
Among the tested pharmaceutical agents, fourteen (namely celecoxib, mebendazole, ivermectin, 
verapamil, promethazine, chlorpromazine, thioridazine, methotrexate, doxorubicin, bleomycin, atorvastatin, 
simvastatin, clotrimazole, and fluconazole) showed antibacterial activity in the tested concentration 
range (0.25–250 µg/mL), while the other agents in the study had no relevant antibacterial properties 
on the bacterial strains used in this study (minimal inhibitory concentrations [MIC] > 250 µg/mL; 
Table 1). The most potent antibacterial activity was noted for chlorpromazine, thioridazine and 
mebendazole (consistently for all tested strains), in addition, MICs were recorded in the moderate 
range regarding the tested statins (for Enterobacter cloacae), promethazine (for Chromobacterium 
violaceum wt85 and CV026), celecoxib (for S. aureus) and ivermectin (for S. aureus). The antibacterial 
activity of the tested antipsychotic drugs became more potent with the progression of the different 
generation drugs (promethazine is a non-selective, first-generation phenothiazine, while thioridazine 
is a newer drug of the same group) [59]; these compounds have been extensively characterized as 
efflux pump inhibitors, while the antibacterial activity of these drugs is partly attributed to their 
intercalation into DNA [60]. Anthracyclines (including doxorubicin) and bleomycin are frequently 
termed ‘anticancer antibiotics’; therefore, it is not surprising that the antibacterial properties of these 
drugs were observed [61,62]. Similarly to the phenothiazines, their antibacterial activity is also 
attributed to bacterial DNA-intercalation, while it is debated whether their potency to produce 
semiquinone-based oxidative free radicals in the presence of Fe2+-ions (which is an important factor 
of their anticancer activity in vivo) is important in this regard [61–64]. Atorvastatin was effective in a 
1–2-fold lower dose than simvastatin; although the exact mechanism of action is uncertain, some 
reports suggest that they interfere with the mevalonate pathway (similarly to eukaryotic cells) and 
the synthesis of the major lipid constituents of cell membrane microdomains [51,65,66]. In line with 
previous reports, ivermectin, celecoxib, and the azole-type antifungal agents were only effective 
against Gram-positive bacteria (in our case S. aureus ATCC 25923) [67–69]. The MIC values recorded 
in this experiment were used to set the starting doses of these drugs in the QS-inhibition assays to 
distinguish between their quorum quenching and antibacterial properties [70]. The MICs of acridine 
orange have been previously reported at 125 µg/mL on the QS-sensor strains (C. violaceum wt85, 
CV026, and Serratia marcescens AS-1) and >250 µg/mL for the other tested bacterial strains [71]. The 
results on the control strains (S. aureus and E. coli ATCC strains) were adequate and in line with 
findings in the literature [59,60,65,67–69]. 
Table 1. Antibacterial activity of tested pharmacological agents (minimal inhibitory concentration 
values; (µg/mL)) *. 
Compounds 
C. 
violaceum 
wt85 
C. 
violaceum 
CV026 
E. 
cloacae 
31298 
S. 
paucimobilis 
Ezf 10-17 
Novosphingobium 
Spp. Rr 2-17 
S. 
marcescens 
AS-1 
E. coli 
ATCC 
25922 
S. aureus 
ATCC 
25923 
celecoxib >250 >250 >250 >250 >250 >250 >250 15.6 
mebendazole 62.5 62.5 125 62.5 62.5 31.3 125 62.5 
ivermectin >250 >250 >250 >250 >250 >250 >250 31.3 
verapamil  >250 >250 >250 250 250 >250 >250 250 
promethazine 31.3 31.3 >250 >250 250 125 >250 >250 
chlorpromazine 15.6 15.6 125 62.5 62.5 62.5 >250 >250 
thioridazine 15.6 15.6 62.5 31.3 31.3 15.6 31.3 125 
methotrexate 125 125 >250 125 125 >250 >250 >250 
doxorubicin 125 125 250 250 250 125 125 62.5 
bleomycin 125 125 125 250 250 >250 125 62.5 
atorvastatin 125 125 31.3 >250 >250 125 >250 62.5 
simvastatin 250 250 62.5 >250 >250 125 >250 125 
clotrimazole >250 >250 >250 >250 >250 >250 >250 125 
fluconazole >250 >250 >250 >250 >250 >250 >250 62.5 
DMSO >2 V/V% >2 V/V% > 2 V/V% >2 V/V% >2 V/V% >2 V/V% >2 V/V% >2 V/V% 
* Pharmacological agents not presented in this table had an MIC > 250 µg/mL for all tested bacterial strains. 
2.2. Screening and Semi-Quantitative Assessment of QS-Inhibitory Activity 
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Among the forty-five tested pharmaceutical compounds, eight drugs (namely 5-fluorouracil, 
metamizole-sodium, cisplatin, methotrexate, bleomycin, promethazine, chlorpromazine, and thioridazine) 
showed relevant QS-inhibitory activity in the cross-inoculation experiments with C. violaceum wt85 
and S. marcescens AS-1; therefore, these compounds were included in the parallel inoculation assay 
(with S. marcescens AS-1, and the C. violaceum CV026 + AHL-producer-pair combinations) to quantify 
the QS-inhibition of these agents, while the other pharmaceutical agents were not tested further; the 
result of these experiments is presented in Figures 1–4 and in the Supplementary Table S1(expressed 
as QS-inhibition zone diameters with SD values for each respective model systems). DMSO, 70% 
ethanol, 85% glycerol, and acetone were also tested as solvent controls in the cross-inoculation 
experiments, where they presented with no QS-inhibitory effects. 
Compared to acridine orange (AO), the QS-inhibitory effects of metamizole-sodium, cisplatin 
and methotrexate were less potent, with 2–10 times smaller QS-inhibition zones), while the 
phenothiazine-derivatives, bleomycin, and 5-fluorouracil exhibited concentration-dependent QS-
inhibitory activity, which was more potent than AO in almost all cases when tested at the same or 
even at lower doses (QS-inhibition zones 1.5–3-times larger than in the case of AO, or the activity in 
doses where the positive control showed no QS-inhibition; Figures 1–4). When it comes to the 
phenothiazines, the potency of QS-inhibition increased with the progression of the different 
generation drugs (promethazine → thioridazine), similarly to their antibacterial activity. 
Interestingly, some agents, which presented with antibacterial activities (celecoxib, mebendazole, 
ivermectin, verapamil, doxorubicin, atorvastatin, simvastatin, clotrimazole, fluconazole) did not show QS-
inhibitory properties, while others (metamizole-sodium, cisplatin) had no antibacterial activity while 
being QS-inhibitors (Figures 1–4). Overall, the most potent QS-inhibitor (among the tested 
pharmaceutical compounds) was 5-fluorouracil, and the S. marcescens model system presented as the 
most sensitive for the QS-inhibitory activity of the tested compounds (i.e., inhibition of prodigiosin 
pigment production), while among the C. violaceum CV026 and AHL-producer pair system, the 
following order may be set up in regards to sensitivity, based on our results: 1. C. violaceum CV026 
and Sphingomonas paucimobilis Ezf 10–17 (most sensitive), 2. C. violaceum CV026 and E. cloacae 31298, 
3. C. violaceum CV026 and Novosphingobium spp. Rr 2–17 (least sensitive) (Figures 1–4.). The 
mechanism of action of the active pharmaceutical drugs has not been described: as signal molecule-
degradation (i.e., quorum quenching by degradation) mainly occurs with compounds with 
enzymatic activity (e.g., the human paraoxonase enzyme, which is essentially a lactonase), findings 
of other studies in the literature suggest that these drugs exert their QS-inhibitory properties through 
inhibition of signal detection or through modifying gene expression in these bacteria [42,47]. 
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Figure 1. Dose-dependent quorum sensing-inhibitory activity of tested compounds. Model system: 
C. violaceum CV026, and E. cloacae 31298 (quorum sensing inhibition zone diameters with SD values 
are in the Supplementary Material). 
 
Figure 2. Dose-dependent quorum sensing-inhibitory activity of tested compounds. Model system: 
C. violaceum CV026, and S. paucimobilis Ezf 10–17 (quorum sensing inhibition zone diameters with SD 
values are in the Supplementary Material). 
 
Figure 3. Dose-dependent quorum sensing-inhibitory activity of tested compounds. Model system: 
C. violaceum CV026, and Novosphingobium spp. Rr 2–17 (quorum sensing inhibition zone diameters 
with SD values are in the Supplementary Material). 
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Figure 4. Dose-dependent QS-inhibitory activity of tested compounds. Model system: S. marcescens 
AS-1. (quorum sensing inhibition zone diameters with SD values are in the Supplementary Material). 
There are several studies reporting on the QS-inhibitory activity of antibiotics (e.g., 
azithromycin, gentamicin, tobramycin, and fluoroquinolones) or the successful use of QS-inhibitory 
compounds together with conventional antibiotics in vitro and in animal models [72–74]. Non-
antibiotic pharmaceutical drugs and compounds derived from various natural sources and foos have 
attracted reasonable attention as novel antibacterial agents or adjuvant compounds (efflux pump 
inhibitors, membrane permeabilizers, QS-inhibitors) because their physicochemical and in vivo 
biological properties have been previously described [25,26,30,39,53], a summary of relevant 
compounds and corresponding literature is presented in Table 2. The characterization of the 
antibacterial and QS-inhibitory activity of the abovementioned compounds was performed through 
the utilization of different in vitro model systems (e.g., Aeromonas spp., Agrobacterium tumefaciens, 
Bacillus subtilis, Burkholderia cepacia, Chromobacterium spp., E. coli, Serratia spp., P. aeruginosa PAO1, V. 
harveyi, S. aureus, S. maltophilia) and molecular testing methods (e.g., detection of differences in gene 
expression levels with PCR) [74-83]. 
Although it is difficult to assess the detected activity of these drug molecules in relation to 
previous publications, because most of these reports used different model systems (e.g., inhibition of 
swarming motility or elastase-, protease-production of P. aeruginosa PAO1, to the detection of gene-
expression changes in P. aeruginosa, S. maltophilia or S. aureus, or experimental animal-based systems, 
where a lung, soft tissue, or other infection models are used), it can be observed that most of the 
mentioned compounds exerted QS-inhibitory properties in the same dose range or in doses 1–2-fold 
lower than in our studies, these differences are presumably due to the different sensitivities of these 
model systems utilized, while in animal systems, the tissue distribution of the compounds should 
also be taken into consideration [65–83]. 
Table 2. Pharmacological agents and food-derived compounds tested for their antibacterial and 
quorum sensing-inhibitory activities. 
Pharmacological agents Food-derived compounds 
acetyl-salicylic acid [84] pepper [108] 
antifungal azoles [67] curcumin [109] 
auranofin [85] horse raddish [110] 
azathioprine [86] flavonoids [111] 
bithionol [87] zeaxantin [112] 
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catecholamines [88] cranberry juice [113] 
celecoxib [69] resveratrol [114] 
coumarines [37,89] betulinic acid [115] 
chloroxazone [57] ajoene [116] 
daunorubicin [90] essential oils [71,113] 
diflunisal [91]  
finasteride [92]  
floxuridine [93]  
glyceryl-trinitrate [94]  
ibuprofen [95]  
ivermectin [68]  
local anesthetics [96,97]  
general anesthetics [96,97]  
metformin [98]  
miltefosine [99]  
niclosamide [100]  
parthenolide [101]  
toremifene [102]  
statins [65,66]  
streptozotocin [93]  
Vitamin A [103]  
Vitamin C [104]  
Vitamin D [103,105,106]  
Vitamin K [107]  
Some reports also suggested that various vitamins have potent adjuvant properties, enhancing the 
bactericidal activity of antibiotics (Table 2), and they also exert their own antibacterial activities in 
very high concentrations [103-107]. Nevertheless, the tested vitamins and antioxidants (Vitamin B1, 
Vitamin B6, Vitamin B12, Vitamin C, Vitamin D, Vitamin E, Coenzyme Q10) did not show any 
antibacterial or QS-inhibitory activity during our experiments. 
Highlights of the study: during our experiments, the antibacterial and QS-inhibitory capacities 
of 45 currently used pharmacological agents (sourced from diverse clinical indications and molecular 
characteristics) have been tested in a semi-quantitative in vitro model, for which such data were not 
available whatsoever, or data were generated on different model systems. Fourteen of the tested drugs 
showed varying degrees of antibacterial activity on the tested bacterial strains, while five drugs 
(promethazine, chlorpromazine, thioridazine, 5-fluorouracil, and bleomycin) showed dose-
dependent QS-inhibitory activity, which was more potent than acridine orange. Based on the results 
of this experiment, the characterization of active pharmaceutical compounds on different QS-based 
model systems is highly recommended, in addition, the continuous screening of the existing drug 
pool may result in the establishment of a library of clinically relevant drugs with virulence-
modulating properties. The in vitro antibacterial properties of the tested drugs highlight the tendency 
of some non-antibiotic pharmacological agents to affect bacterial viability, which is important in the 
context of the human gut microbiome: in addition to antibiotics, these drugs may also have 
detrimental effects on the species composition of gut bacteria (leading to disease), therefore this study 
provides novel insights in this aspect as well [118]. 
Limitations of the study: during our experiments, the QS-inhibitory activity of the compounds 
was only tested against strains, where cell-cell communication is based on AHL-signal molecules and 
their activity was not characterized on the genetic level with molecular methods. To further establish 
the QS-inhibitory and anti-virulence properties of the tested drugs, further experiments with 
additional Gram-positive (e.g., including AI-2-producing Bacillus species, toxin-producing S. aureus), 
and Gram-negative (e.g., elastase-production and motility-assays with P. aeruginosa (PQS-mediated), 
S. maltophilia (DSF-mediated) bacterial model systems should be considered. 
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3. Materials and Methods 
3.1. Chemicals 
3.1.1. Pharmaceutical Compounds 
Forty-five pharmacological agents, encompassing a wide variety of different chemical structures 
and mechanisms of action were tested during our experiments: 1. non-steroidal anti-inflammatory 
drugs (NSAIDs): acetylsalicylic acid (Sigma-Aldrich; Budapest, Hungary; will be listed as SA in the 
subsequent text), indomethacin (Sanofi; Paris, France; will be listed as SP in the subsequent text), 
metamizole-sodium (SF), diclofenac (SA), celecoxib (Pfizer Hungary Ltd.; Budapest, Hungary), 
acetaminophen (SA), 2. antiviral and antifungal drugs: acyclovir (Teva Pharmaceuticals; Petah Tikva, 
Israel; will be listed as TPh in the subsequent text), cidofovir (SA), amantadine (SA), clotrimazole 
(TPh), fluconazole (SA), terbinafine (GlaxoSmithKline Hungary Ltd., Budapest, Hungary), 3. 
anthelmintic drugs: mebendazole (Richter Pharmaceuticals; Budapest, Hungary; will be listed as RPh 
in the subsequent text), ivermectin (SA), 4. anti-allergy medications (H1-receptor antagonists and 
decongestants): cetirizine (SA), azelastine (SA), xylomethazoline (SA), 5. drugs targeting the 
cardiovascular system: metoprolol succinate (SA), enalapril maleate (SA), valsartan (SA), verapamil 
(TPh), simvastatin (SA), atorvastatin (SA), 6. mucolytics and antitussives: ambroxol (TPh), acetyl-
cysteine (TPh), guaifenesin (SA), 7. neuroleptic drugs: promethazine (SA), chlorpromazine (SA), 
thioridazine (SA), 8. antimetabolite anticancer agents: methotrexate (Ebewe Pharma, Unterach am 
Attersee, Austria), 5-fluorouracil (TPh), gemcitabine (TPh), 9. alkylating anticancer agents: 
cyclophosphamide (Baxter; Deerfield, IL, United States), cisplatin (TPh), 10. anticancer drugs 
affecting the microtubule system or topoisomerase-enzymes: vincristine (TPh), paclitaxel (TPh), 
doxorubicin (TPh), topotecan (SA), bleomycin (TPh), 11. vitamins and antioxidants: Vitamin B1 
(EGIS Pharmaceuticals; Budapest, Hungary; will be listed as EGIS in the subsequent text), Vitamin B6 
(EGIS), Vitamin B12 (RPh), Vitamin C (SA), Vitamin D (EGIS), Vitamin E (SA), Coenzyme Q10 (SA). 
Pharmaceutical compounds were dissolved in phosphate-buffered saline, with the exception of 
simvastatin and atorvastatin, which were dissolved in DMSO, in addition to Vitamin D and 
Coenzyme Q10, which were dissolved in acetone and 70% ethanol, respectively. 
3.1.2. Media Constituents and Other Reagents 
Bacteriological agar (Bio-Rad Hungary Ltd.; Budapest, Hungary), tryptone (Thermo Fischer 
Scientific; Waltham, MA, USA; will be listed as TFS in the subsequent text), yeast extract (TFS), D-
glucose (SA), kanamycin (SA), NaCl (SA), K2HPO4 (SA), KH2PO4 (SA), MgSO4 × 7H2O (SA), CaCl2 × 
2H2O (SA), FeSO4 × 7H2O (SA), Na2EDTA (SA), MnSO4 × 7H2O (SA), ZnSO4 × 7H2O (SA), Na2MoO4 × 
2H2O (SA), CoCl2 × 6H2O (SA), dimethyl-sulfoxide (DMSO; SA), acetone (SA), acridine orange (AO; 
SA), 70% ethanol (SA), 85% glycerol (SA), and phosphate-buffered saline (PBS; SA). During the 
preparation of the modified Luria-Bertani agar (LB*-A, Bio-Rad Hungary Ltd.; Budapest, Hungary), 
the following stock solutions were used: 5% Fe-EDTA stock solution, 3% CaCl2 stock solution, and a 
microelement stock solution (containing 1.0 g MnSO4 × 7H2O, 0.5 g ZnSO4 × 7H2O, 25 mg Na2MoO4 × 
2H2O and 2.5 mg CoCl2 × 6H2O per 100 mL). The stock solutions were aliquoted in 50 mL centrifuge 
tubes and kept at –20 °C till use. 
3.2. Bacterial Strains 
The following bacterial strains were used during our QS-inhibition experiments: 
Chromobacterium violaceum wt85 (wild-type strain, characterized by the AHL signal molecule-
mediated production of the purple violacein pigment, capable of the production of endogenous QS-
signal molecule (N-hexanoyl-L-HSL)), C. violaceum CV026 (Tn5 transposase-mutant, AHL-signal 
molecule indicator strain: incapable of endogenous QS-signal molecule-production, but produces 
purple violacein pigment in the presence of external AHL stimuli) [70,71], Enterobacter cloacae clinical 
isolate no. 31298 (isolated from a wound sample, AHL-producing-strain (used with C. violaceum 
CV026)) [70,71,], Sphingomonas paucimobilis Ezf 10–17 (isolated from a tumor of the “Ezertűfű” variety 
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of the common grapevine (Vitis vinifera), AHL-producing-strain (used with C. violaceum CV026)), 
Novosphingobium spp. Rr 2–17 (isolated from a tumor of the “Rajnai rizling” variety of the common 
grapevine (Vitis vinifera), AHL-producing-strain (used with C. violaceum CV026)) [119], Serratia 
marcescens AS-1 (characterized by the production AHL signal molecule-mediated production of the 
orange-red pigment prodigiosin (2-methyl-3-pentyl-6-methoxyprodigiosin), capable of endogenous 
QS-signal molecule-production (N-hexanoyl-L-HSL)) [120]. In addition, Staphylococcus aureus ATCC 
25923 and Escherhichia coli ATCC 25922 were used as control strains. 
The QS-sensory and indicator of bacterial strains for our experiments were kindly provided by 
Dr. Ernő Szegedi (Institute of Viticulture and Enology, National Agricultural Research Center; 
Badacsonytomaj, Hungary). For shorter time periods (<1 month), the bacterial strains were 
maintained on Luria-Bertani (LB) agar, while for longer periods, the strains were kept in a –80 °C 
freezer, in a 1:4 mixture of 85% glycerol and liquid Luria-Bertani (LB-B) medium. For the maintenance 
purposes of C. violaceum CV026, the media were also supplemented with kanamycin. 
3.3. Culture Media 
The following culture media were used during our experiments: cation-adjusted Mueller–
Hinton broth (CMH-B; Bio-Rad Hungary Ltd., Budapest, Hungary), Luria–Bertani broth (LB-B), and 
Luria–Bertani agar (LB-A) (Bio-Rad Hungary Ltd., Budapest, Hungary) which were purchased, while 
the modified Luria–Bertani agar (LB*-A) (which was used during the QS-inhibition assays; 
containing 8.0 g tryptone, 5.0 g yeast extract, 5.0 g NaCl, 2.0 g D-glucose, 1.0 g K2HPO4, 0.2 g MgSO4 
× 7H2O, 10 mL 3% CaCl2 stock solution, 5 mL Fe-EDTA stock solution, 1 mL microelement stock 
solution, and 12.0 g of bacteriological agar per 1 L of media; pH was adjusted to 7.0–7.2) was prepared 
in-house [71]. 
3.4. Antibacterial Activity 
As a part of our study, the antibacterial activity of non-antibiotic pharmaceutical compounds on 
QS-sensory and signal molecule-producing bacterial strains was determined. The purpose of the 
assay was to screen for possible antibacterial activity of the tested compounds so that later on, their 
potential QS-inhibitory activities and their bacterial population density-reducing properties (due to 
their bacteriostatic or bactericidal effects) in the subsequent QS-inhibition assays could be 
distinguished. The minimum inhibitory concentrations (MICs) of the tested compounds were 
determined using the standard broth microdilution (BMD) method, based on the recommendations 
of the Clinical and Laboratory Standards Institute (CLSI; M07-A10). The experiments were performed 
in 96-well polystyrene microtiter plates, using cation-adjusted Mueller–Hinton broth (CMH-B), the 
tested concentrations of the compounds were ranging between 0.25–250 µg/mL. During the 
experiments with S. aureus ATCC 25922, CMH-B was supplemented by 2% NaCl. The plates were 
incubated at 37 °C in an air thermostat; the MIC values of the tested compounds were recorded after 
16–18 h of incubation; the interpretation of the results was performed using a photometer. S. aureus 
ATCC 25923 and E. coli ATCC 25922 were tested as control strains. All experiments were performed 
in triplicate. 
3.5. Screening for and Semi-Quantitative of QS-Inhibitory Activity Using Disk Diffusion Method 
The screening and quantification of the QS-inhibitory activity of the tested compounds were 
performed using the disk diffusion method, the detailed description and optimization of these 
methods were previously described [71,101,121]. Screening for the QS-inhibitory activity of the tested 
compounds was performed using the cross-inoculation method (see Supplementary Material S3). 
Briefly, overnight bacterial cultures of C. violaceum wt85 and S. marcescens AS-1 (at OD580 ~ 0.5) grown 
in LB-B broth were inoculated directly onto LB*-A agar surface in a crossing pattern (see 
Supplementary Figure S2). Filter paper disks (7.0 mm in diameter, Whatman 3MM) were 
impregnated with 10 µL of the solutions of the tested compounds (at 1.56–50 µg/mL, depending on 
the MICs of the respective drugs, see Section 4.4), which were placed at the center of the crossing 
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pattern right after the plates were inoculated. Before the evaluation, the plates were incubated for 48 
h at room temperature. 
If detectable QS-inhibition (discolored, but intact bacterial colonies around the treated paper 
disk) was observed for a tested pharmaceutical compound, their QS-inhibitory activity was 
quantified using the parallel inoculation method (Figures 5–6). Pair combinations of the used sensor 
strain C. violaceum CV026 and the AHL-signal-producing strains (either E. cloacae 31298, S. 
paucimobilis Ezf 10–17 or Novosphingobium spp. Rr 2–17) were inoculated directly onto the LB*-A agar 
surface in parallel, at a 5 mm distance from each other, while S. marcescens AS-1 was inoculated as a 
single line (capable of producing prodigiosin from endogenous AHL-signals) [71,101,121]. Filter 
paper disks (impregnated with 10 µL of the solutions of the different solutions of the tested 
compounds) were placed on the center of the inoculated line(s). To quantify the QS inhibitory effect 
of the drugs, the diameter of the QS-inhibition zones (i.e., the size of discolored bacterial colonies 
with no growth inhibition) around the disks was measured using a caliper. The results of the studies 
are derived from the average of at least five independent experiments. 
 
Figure 5. Semi-quantitative QS-inhibition assay, using parallel inoculation disk diffusion method, 
using C. violaceum CV026, and E. cloacae 31298 (left), and S. marcescens AS-1 (right). 
 
Figure 6. Presentation of positive and negative controls during semi-quantitative QS-inhibition assay, 
using parallel inoculation disk diffusion method, Left: C. violaceum CV026 and Sphingomonas 
paucimobilis Ezf 10–17 (one effective compounds can be observed in the lower right corner); Right: S. 
marcescens AS-1 (two effective compound can be observed on the left side and center).Activity is 
represented as discolored bacterial colonies with no detected growth inhibition. 
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4. Conclusions 
Infections caused by MDROs are associated with excess morbidity (sequelae, decrease in the 
quality of life) and mortality worldwide. Since the 21st century, antibacterial drug development has 
been slow to keep up with the rapid developments in the levels of bacterial resistance. Anti-virulence 
may offer a new wave of potential antibacterial therapeutics in the future, which drugs that will 
presumably have longer periods of clinical usefulness, compared to antibiotics. QS-based modulation 
of bacterial virulence is a straightforward and attractive drug development avenue. Nowadays, 
several thousands of drug compounds are marketed for human therapeutic purposes: these 
pharmaceuticals may be considered as a potentially untapped source of QS-inhibitory agents with 
different chemical structures and mechanisms of action, as the pharmacokinetic parameters and 
tolerability of these compounds have already been demonstrated in vivo. In our experiments, we 
have demonstrated the antibacterial and QS-inhibitory effects of various pharmaceutical molecules, 
contributing to the ‘chemical information space’ of QS-inhibition. Based on our promising results, 
further experiments involving the screening of additional pharmaceutical compounds and the 
utilization of more model systems are warranted. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1. Figure S1: Results of a 
literature search in the PubMed/MEDLINE database on the keywords “quorum sensing” and “quorum 
quenching”, Figure S2: Screening for QS-inhibitory activity with the cross-inoculation disk diffusion method, 
using Chromobacterium violaceum wt85 (left) and) and Serratia marcescens AS-1 (right), Table S1: Quorum 
sensing-inhibitory activity of selected pharmacological agents .  
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